Attenua, Inc., a Mountain View, CA-based clinical-stage biopharmaceutical company focused on developing novel medicines to treat cough, completed a $35m Series A financing.
The round was led by Omega Funds with participation from a syndicate of international healthcare investors including Abingworth, OrbiMed and Redmile Group LLC.
The company intends to use the new capital to further develop its lead drug candidate ATA-101, which targets a new mechanism for chronic cough, in Phase 2 clinical trials, as well as to progress its pipeline.
In conjunction with the funding, Michael Kitt, MD, joined Attenua as CEO. He was previously Chief Medical Officer at Afferent Pharmaceuticals, Inc., where he led clinical trials in cough leading to the company’s $1.25 billion acquisition by Merck & Co., Inc in 2016. He, Dina Chaya, Advisor to Omega Funds; Kurt von Emster, Managing Partner at Abingworth; and Rishi Gupta, Private Equity Partner at OrbiMed, will join Attenua’s board of directors. They will join existing members Hugh Rienhoff, Chairman, and Jing Liang, PhD, Founder and Former CEO of Attenua.
Attenua is a clinical-stage biotechnology company developing novel medicines for the millions of patients who suffer from chronic respiratory disorders such as chronic cough.